title: Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease.
authors.forename: Romain
authors.initials: R
authors.lastname: Coriat
authors.forename: Olivier
authors.initials: O
authors.lastname: Mir
authors.forename: Sarah
authors.initials: S
authors.lastname: Leblanc
authors.forename: Stanislas
authors.initials: S
authors.lastname: Ropert
authors.forename: Catherine
authors.initials: C
authors.lastname: Brezault
authors.forename: Stanislas
authors.initials: S
authors.lastname: Chaussade
authors.forename: François
authors.initials: F
authors.lastname: Goldwasser
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000188:drug therapy*; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000139:chemically induced / Q000188:drug therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab